CFO4Life Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $718K | Sell |
25,583
-1,413
| -5% | -$37.6K | 0.11% | 91 |
|
|
2025
Q4 | $672K | Buy |
26,996
+193
| +0.7% | +$4.87K | 0.1% | 101 |
|
|
2025
Q3 | $683K | Buy |
26,803
+762
| +3% | +$18.8K | 0.1% | 102 |
|
|
2025
Q2 | $631K | Buy |
26,041
+707
| +3% | +$16.5K | 0.1% | 105 |
|
|
2025
Q1 | $642K | Sell |
25,334
-3,391
| -12% | -$88.7K | 0.11% | 98 |
|
|
2024
Q4 | $762K | Buy |
28,725
+614
| +2% | +$16.7K | 0.13% | 87 |
|
|
2024
Q3 | $814K | Buy |
28,111
+863
| +3% | +$25.2K | 0.14% | 85 |
|
|
2024
Q2 | $762K | Buy |
27,248
+1,545
| +6% | +$42.5K | 0.14% | 86 |
|
|
2024
Q1 | $713K | Buy |
25,703
+985
| +4% | +$27.3K | 0.13% | 92 |
|
|
2023
Q4 | $712K | Sell |
24,718
-1,078
| -4% | -$32.6K | 0.14% | 89 |
|
|
2023
Q3 | $856K | Sell |
25,796
-2,452
| -9% | -$86.7K | 0.2% | 62 |
|
|
2023
Q2 | $1.04M | Sell |
28,248
-300
| -1% | -$11.7K | 0.22% | 54 |
|
|
2023
Q1 | $1.16M | Sell |
28,548
-200
| -0.7% | -$8.64K | 0.26% | 44 |
|
|
2022
Q4 | $1.47M | Buy |
28,748
+1,295
| +5% | +$62.1K | 0.31% | 51 |
|
|
2022
Q3 | $1.2M | Sell |
27,453
-1,670
| -6% | -$81.1K | 0.32% | 42 |
|
|
2022
Q2 | $1.48M | Sell |
29,123
-2,854
| -9% | -$145K | 0.37% | 42 |
|
|
2022
Q1 | $1.66M | Sell |
31,977
-656
| -2% | -$34K | 0.35% | 41 |
|
|
2021
Q4 | $1.93M | Sell |
32,633
-1,526
| -4% | -$75.6K | 0.4% | 38 |
|
|
2021
Q3 | $1.47M | Buy |
34,159
+2,958
| +9% | +$131K | 0.34% | 40 |
|
|
2021
Q2 | $1.22M | Sell |
31,201
-2,227
| -7% | -$86.6K | 0.28% | 44 |
|
|
2021
Q1 | $1.21M | Sell |
33,428
-3,707
| -10% | -$132K | 0.3% | 44 |
|
|
2020
Q4 | $1.37M | Buy |
37,135
+2,175
| +6% | +$79.8K | 0.39% | 38 |
|
|
2020
Q3 | $1.22M | Buy |
34,960
+304
| +0.9% | +$10.7K | 0.41% | 34 |
|
|
2020
Q2 | $1.07M | Sell |
34,656
-750
| -2% | -$25.5K | 0.41% | 38 |
|
|
2020
Q1 | $1.1M | Sell |
35,406
-2,679
| -7% | -$91.3K | 0.59% | 29 |
|
|
2019
Q4 | $1.42M | Sell |
38,085
-2,364
| -6% | -$84.2K | 0.6% | 33 |
|
|
2019
Q3 | $1.38M | Sell |
40,449
-18,395
| -31% | -$669K | 0.62% | 33 |
|
|
2019
Q2 | $2.42M | Buy |
58,844
+2,028
| +4% | +$80.5K | 1.11% | 22 |
|
|
2019
Q1 | $2.29M | Sell |
56,816
-7,243
| -11% | -$290K | 1.07% | 22 |
|
|
2018
Q4 | $2.65M | Sell |
64,059
-2,737
| -4% | -$114K | 1.17% | 22 |
|
|
2018
Q3 | $2.79M | Sell |
66,796
-29
| -0% | -$1.12K | 1.24% | 21 |
|
|
2018
Q2 | $2.3M | Buy |
66,825
+60,376
| +936% | +$2.06M | 0.96% | 24 |
|
|
2018
Q1 | $217K | Sell |
6,449
-101
| -2% | -$3.47K | 0.18% | 82 |
|
|
2017
Q4 | $225K | Buy |
6,550
+200
| +3% | +$6.82K | 0.18% | 92 |
|
|
2017
Q3 | $215K | Sell |
6,350
-477
| -7% | -$15.3K | 0.17% | 94 |
|
|
2017
Q2 | $218K | Buy |
6,827
+373
| +6% | +$11.8K | 0.2% | 79 |
|
|
2017
Q1 | $209K | Buy |
+6,454
| New | +$203K | 0.19% | 89 |
|
Other funds holding PFE
VCM
VPM
CFO4Life Group's PFE Position: Q1 2026 in Review
CFO4Life Group reduced its Pfizer (PFE) stake by 5.2% in Q1 2026, selling an estimated $37.6K and leaving 25,583 shares worth $718K. The position accounts for 0.11% of the portfolio, ranked #91.
CFO4Life Group first reported a position in PFE in Q1 2017 and has held it in 37 quarters since. The position peaked at $2.79M in Q3 2018. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- CFO4Life Group held 25,583 shares of Pfizer worth $718K as of Q1 2026.
- CFO4Life Group sold 1,413 Pfizer shares in Q1 2026, an estimated $37.6K.
- Pfizer made up 0.11% of CFO4Life Group's portfolio in Q1 2026, its #91 holding.
- CFO4Life Group first reported a position in Pfizer in Q1 2017 and has held it in 37 quarters since.
- CFO4Life Group's Pfizer position peaked at $2.79M in Q3 2018.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on CFO4Life Group's 13F filing for Q1 2026, filed 11 May 2026.